Pacira BioSciences, Inc. $PCRX Position Increased by Pacer Advisors Inc.

Pacer Advisors Inc. boosted its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 24.5% in the first quarter, HoldingsChannel reports. The firm owned 235,427 shares of the company’s stock after purchasing an additional 46,284 shares during the quarter. Pacer Advisors Inc.’s holdings in Pacira BioSciences were worth $5,321,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Dimensional Fund Advisors LP increased its position in Pacira BioSciences by 0.5% in the third quarter. Dimensional Fund Advisors LP now owns 2,163,473 shares of the company’s stock worth $55,751,000 after buying an additional 11,831 shares during the period. Balyasny Asset Management L.P. boosted its holdings in shares of Pacira BioSciences by 36.1% during the second quarter. Balyasny Asset Management L.P. now owns 2,130,733 shares of the company’s stock valued at $50,925,000 after acquiring an additional 565,288 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Pacira BioSciences by 49.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock valued at $27,454,000 after acquiring an additional 367,869 shares during the period. Impax Asset Management Group plc grew its position in shares of Pacira BioSciences by 25.0% during the fourth quarter. Impax Asset Management Group plc now owns 750,027 shares of the company’s stock worth $19,411,000 after acquiring an additional 150,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Pacira BioSciences by 7.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 676,352 shares of the company’s stock worth $17,504,000 after acquiring an additional 49,079 shares during the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Lauren Riker sold 6,115 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $23.50, for a total value of $143,702.50. Following the completion of the sale, the senior vice president owned 62,284 shares of the company’s stock, valued at $1,463,674. This represents a 8.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on PCRX shares. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Pacira BioSciences in a report on Wednesday, July 1st. Weiss Ratings raised shares of Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, May 20th. Needham & Company LLC upped their target price on shares of Pacira BioSciences from $32.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Royal Bank Of Canada raised their price target on shares of Pacira BioSciences from $24.00 to $25.00 and gave the company a “sector perform” rating in a research note on Wednesday. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $29.80.

Key Pacira BioSciences News

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Pacira reported second-quarter revenue of $192.4 million, up 6.2% year over year and above the $191.1 million analyst consensus. Adjusted EPS of $0.73 also exceeded expectations of $0.65. Pacira BioSciences Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management said it continues to execute its “5×30” strategy, highlighting durable cash flow, pipeline progress and commercial partnerships. Pacira is also targeting access to 160 million covered lives for EXPAREL, which could support broader product adoption. Pacira 2026 Revenue Guidance and EXPAREL Coverage
• Positive Sentiment: Needham raised its price target on PCRX from $32 to $33 and maintained a Buy rating, implying substantial potential upside based on the referenced share price. Benzinga Analyst Update
• Neutral Sentiment: Royal Bank of Canada increased its target from $24 to $25 but retained a Sector Perform rating, signaling limited expected upside and a more cautious view. Benzinga Analyst Update
• Negative Sentiment: Pacira guided to 2026 revenue of $735 million to $760 million, below the approximately $767.8 million consensus estimate. The lowered outlook suggests slower-than-expected growth and was the primary negative catalyst for PCRX despite the strong second-quarter results. Pacira 2026 Revenue Guidance

Pacira BioSciences Stock Down 10.0%

Shares of Pacira BioSciences stock opened at $24.87 on Thursday. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.73 and a quick ratio of 3.35. Pacira BioSciences, Inc. has a 1-year low of $18.80 and a 1-year high of $27.66. The business’s fifty day moving average price is $24.61 and its two-hundred day moving average price is $23.35. The company has a market capitalization of $978.63 million, a P/E ratio of 71.06 and a beta of 0.27.

Pacira BioSciences (NASDAQ:PCRX) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.08. The company had revenue of $192.40 million during the quarter, compared to analysts’ expectations of $191.06 million. Pacira BioSciences had a return on equity of 9.61% and a net margin of 1.96%.The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.74 earnings per share. As a group, research analysts forecast that Pacira BioSciences, Inc. will post 1.94 EPS for the current year.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.